A study, led by Zhimin Lu, M.D., Ph.D., professor of neuro-oncology at The University of Texas MD Anderson Cancer Center, showcased the non-metabolic abilities of PKM2 (pyruvate kinase M2) in promoting tumor cell proliferation when cells produce more of the enzyme. The study results were published in today’s issue of Nature Communications…
ASPS tumor cells contain a chromosomal translocation — strands of DNA from two chromosomes trade places. The two strands fuse together to create a new gene, ASPSCR1-TFE3 that functions differently than either “parent” gene…
The immune system is designed to remove things not normally found in the body. Cells undergoing change, e.g…
BCS has been a standard of excellence in breast cancer care and its use for management of early-stage breast cancer had increased steadily since the 1990s. …
Cancer stem cells are particularly difficult to eradicate and are at the heart of why it is so hard to more effectively treat cancer patients, as the post-treatment survival of cancer stem cells drives tumor recurrence, the systemic spread of cancer and, ultimately, treatment failure. The researchers, based at the University’s Institute of Cancer Sciences and the Cancer Research UK Manchester Institute — both part of the Manchester Cancer Research Centre — investigated the role of mitochondria which produce and release energy within cells…
International guidelines recommend annual follow-up mammograms for every woman after treatment for early breast cancer, regardless of the risk of her cancer returning. There is also no strong evidence to support annual mammography compared with other possible mammography schedules. …
Compression of the breast is necessary in mammography to optimize image quality and minimize absorbed radiation dose. …
Published today in Nature, the study examined an antibody (MPDL3280A) which blocks a protein (PD-L1) thought to help cancer cells evade immune detection. In a phase one, multi-centre international clinical trial, 68 patients with advanced bladder cancer (who had failed all other standard treatments such as chemotherapy) received MPDL3280A, a cancer immunotherapy medicine being developed by Roche. In addition, patients were all tested for the protein PD-L1 and around 30 were identified as having PD-L1 positive tumours. After six weeks of treatment, 43 per cent of PD-L1-positive patients found their tumour had shrunk…
Whether to remove ovaries at hysterectomy for reasons other than cancer is a subject of hot debate. Removing them reduces the risk of breast cancer and dramatically reduces the risk of ovarian cancer. On the other hand, studies have associated removing ovaries with increased risk of death, cardiovascular disease, lung cancer, and osteoporosis and with declines in cognitive ability and sexual function. And many assumed that removing ovaries would also increase the risk of pelvic organ prolapse. …
Published today in Nature, the study examined an antibody (MPDL3280A) which blocks a protein (PD-L1) thought to help cancer cells evade immune detection. In a phase one, multi-centre international clinical trial, 68 patients with advanced bladder cancer (who had failed all other standard treatments such as chemotherapy) received MPDL3280A, a cancer immunotherapy medicine being developed by Roche. In addition, patients were all tested for the protein PD-L1 and around 30 were identified as having PD-L1 positive tumours. After six weeks of treatment, 43 per cent of PD-L1-positive patients found their tumour had shrunk…